EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Psoriatic Arthritis: Pathogenesis and Targeted Therapies

Ana Belén Azuaga, Julio Ramírez, Juan D Cañete iD

International Journal of Molecular Sciences · 03.03.2023 · 24 (5) · 4901

DOI: 10.3390/ijms24054901 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.03.2023. Verfasst von Ana Belén Azuaga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, 08036 Barcelona, Spain. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 186-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory immune-mediated disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and dactylitis), generally occurs in patients with psoriasis. PsA is also associated with uveitis and inflammatory bowel disease (Crohn’s disease and ulcerative colitis). To capture these manifestations as well as the associated comorbidities, and to recognize their underlining common pathogenesis, the name of psoriatic disease was coined. The pathogenesis of PsA is complex and multifaceted, with an interplay of genetic predisposition, triggering environmental factors, and activation of the innate and adaptive immune system, although autoinflammation has also been implicated. Research has identified several immune-inflammatory pathways defined by cytokines (IL-23/IL-17, TNF), leading to the development of efficacious therapeutic targets. However, heterogeneous responses to these drugs occur in different patients and in the different tissues involved, resulting in a challenge to the global management of the disease. Therefore, more translational research is necessary in order to identify new targets and improve current disease outcomes. Hopefully, this may become a reality through the integration of different omics technologies that allow better understanding of the relevant cellular and molecular players of the different tissues and manifestations of the disease. In this narrative review, we aim to provide an updated overview of the pathophysiology, including the latest findings from multiomics studies, and to describe current targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticPsoriasisHumansComorbidityCytokines

Stichwörter der Autor:innen

JAK inhibitorsbiological therapycytokinesimmune cellsmultiomicspathogenesispsoriatic arthritissingle-cell RNA sequencingsynovial fibroblaststissue heterogeneity

Substanzen

Cytokines

Autor:innen und Institutionen

  • Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, 08036 Barcelona, Spain.

ORCID-Profile: Juan D Cañete

Zitieren

APA

Azuaga, A. B., Ramírez, J., & Cañete, J. D. (2023). Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences, 24(5), 4901. https://doi.org/10.3390/ijms24054901

Vancouver

Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences. 2023;24(5):4901. doi:10.3390/ijms24054901

BibTeX
@article{Azuaga2023,
  author = {Azuaga, Ana Belén and Ramírez, Julio and Cañete, Juan D},
  title = {Psoriatic Arthritis: Pathogenesis and Targeted Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {4901},
  doi = {10.3390/ijms24054901}
}
Kostenlos starten →